574 related articles for article (PubMed ID: 29486770)
21. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
[TBL] [Abstract][Full Text] [Related]
22. O6-Methyguanine-DNA Methyl Transferase (MGMT) Promoter Methylation in Serum DNA of Iranian Patients with Colorectal Cancer.
Alizadeh Naini M; Kavousipour S; Hasanzarini M; Nasrollah A; Monabati A; Mokarram P
Asian Pac J Cancer Prev; 2018 May; 19(5):1223-1227. PubMed ID: 29801405
[TBL] [Abstract][Full Text] [Related]
23. CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.
Li X; Hu F; Wang Y; Yao X; Zhang Z; Wang F; Sun G; Cui BB; Dong X; Zhao Y
Biomed Res Int; 2014; 2014():236361. PubMed ID: 25243122
[TBL] [Abstract][Full Text] [Related]
24. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker.
Nishio M; Sakakura C; Nagata T; Komiyama S; Miyashita A; Hamada T; Kuryu Y; Ikoma H; Kubota T; Kimura A; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Ida H; Ito K; Chiba T; Ito Y; Otsuji E
Anticancer Res; 2010 Jul; 30(7):2673-82. PubMed ID: 20682997
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer.
Gyparaki MT; Basdra EK; Papavassiliou AG
J Mol Med (Berl); 2013 Nov; 91(11):1249-56. PubMed ID: 24057814
[TBL] [Abstract][Full Text] [Related]
26. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
[TBL] [Abstract][Full Text] [Related]
27. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
28. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.
Roperch JP; Incitti R; Forbin S; Bard F; Mansour H; Mesli F; Baumgaertner I; Brunetti F; Sobhani I
BMC Cancer; 2013 Dec; 13():566. PubMed ID: 24289328
[TBL] [Abstract][Full Text] [Related]
29. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
30. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
[TBL] [Abstract][Full Text] [Related]
31. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.
Ogino S; Odze RD; Kawasaki T; Brahmandam M; Kirkner GJ; Laird PW; Loda M; Fuchs CS
Am J Surg Pathol; 2006 Sep; 30(9):1175-83. PubMed ID: 16931963
[TBL] [Abstract][Full Text] [Related]
32. Stage-differentiated ensemble modeling of DNA methylation landscapes uncovers salient biomarkers and prognostic signatures in colorectal cancer progression.
Muthamilselvan S; Raghavendran A; Palaniappan A
PLoS One; 2022; 17(2):e0249151. PubMed ID: 35202405
[TBL] [Abstract][Full Text] [Related]
33. Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer.
Meng H; Li W; Boardman LA; Wang L
BMC Cancer; 2018 Apr; 18(1):433. PubMed ID: 29661177
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
35. Sensitive and Noninvasive Detection of Aberrant SFRP2 and MGMT-B Methylation in Iranian Patients with Colon Polyps.
Naini MA; Mokarram P; Kavousipour S; Zare N; Atapour A; Zarin1 MH; Mehrabani G; Borji M
Asian Pac J Cancer Prev; 2016; 17(4):2185-93. PubMed ID: 27221916
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the DNA methylation level of cancer-related genes in colorectal cancer and the surrounding normal mucosa.
Sugai T; Yoshida M; Eizuka M; Uesugii N; Habano W; Otsuka K; Sasaki A; Yamamoto E; Matsumoto T; Suzuki H
Clin Epigenetics; 2017; 9():55. PubMed ID: 28533824
[TBL] [Abstract][Full Text] [Related]
37. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
[TBL] [Abstract][Full Text] [Related]
38. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.
Baba Y; Huttenhower C; Nosho K; Tanaka N; Shima K; Hazra A; Schernhammer ES; Hunter DJ; Giovannucci EL; Fuchs CS; Ogino S
Mol Cancer; 2010 May; 9():125. PubMed ID: 20507599
[TBL] [Abstract][Full Text] [Related]
39. Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.
Bae JM; Kim JH; Kwak Y; Lee DW; Cha Y; Wen X; Lee TH; Cho NY; Jeong SY; Park KJ; Han SW; Lee HS; Kim TY; Kang GH
Br J Cancer; 2017 Apr; 116(8):1012-1020. PubMed ID: 28278514
[TBL] [Abstract][Full Text] [Related]
40. Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype.
Gebhard C; Mulet-Lazaro R; Glatz D; Schwarzfischer-Pfeilschifter L; Schirmacher P; Gaedcke J; Weichert W; Reuschel E; Dietmaier W; Rehli M
Int J Cancer; 2022 Feb; 150(4):617-625. PubMed ID: 34591983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
